Monarch Med Spa – FDA Warning Letter

The FDA issued a Warning Letter to Monarch Med Spa following a review of its website, www.monarchmedispa.com, which promotes LipoDissolve products. The FDA determined that these products are unapproved drugs, specifically prescription drugs, as they are intended to treat medical conditions or affect body function and require professional supervision. The primary violation is that the LipoDissolve products are misbranded under sections 502(a), 502(n), and 201(n) of the FDCA [21 U.S.C. §§ 352(a), 352(n), 321(n)] and 21 CFR 202.1(e)(5)(i), (e)(6)(i) due to false or misleading claims in their labeling and advertising. Specifically, the website makes unsubstantiated efficacy claims (e.g., fat cell breakdown, specific fat loss), unsubstantiated superiority claims (e.g., less discomfort than liposuction, more certain results than Mesotherapy), and unsubstantiated safety claims (e.g., natural homeopathic ingredient, proven safety). The FDA is unaware of evidence supporting these claims. Monarch Med Spa must take prompt corrective action within fifteen working days, providing a written response detailing steps taken to correct violations and prevent recurrence. Failure to comply may lead to legal action, including seizure and injunction, and may impact future federal contracts.